ABVC Biopharma, Inc.
2.7700-0.13 (-4.48%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · ABVC · USD
Key Stats
Market Cap
65.21MP/E (TTM)
-Basic EPS (TTM)
-0.25Dividend Yield
0%Recent Filings
8-K
ABVC assets double in Q2
ABVC BioPharma reported Q2 2025 results with total assets surging 103% to $16.2 million from $8.0 million a year earlier, fueled by affiliate equity gains and better allocation. Shareholders' equity climbed to $9.5 million, while diluted EPS loss narrowed to $(0.13) from full-year 2024's $(0.42). Post-quarter, the company acquired $3.3 million Taiwan farmland for R&D and GMP expansion, plus $350K July licensing revenue from partners. This bolsters vertical integration but hinges on regulatory approvals.
10-Q
Q2 FY2025 results
ABVC BioPharma posted zero revenue in Q2 FY2025 ended June 30, 2025, down 100% y/y from $117K, while operating expenses climbed 135% y/y to $2.3M on higher stock-based compensation, yielding an operating loss of $2.3M, up 167% y/y. Net loss widened to $2.3M or $0.13 per diluted share from $1.0M or $0.08, with the gap to operating loss tied to $1.6M in stock-based comp and $129K interest expense. Cash dipped to $388K from $248K y/y, but total assets swelled to $16.2M on $7.7M land acquisition in Taiwan via AiBtl shares; working capital deficit narrowed to $3.8M. Financing inflows of $2.4M from private placements and warrant exercises offset $1.4M operating cash burn. Yet Nasdaq compliance hangs by a thread on equity and bid price rules.
8-K
Shareholders approve key proposals
ABVC BioPharma shareholders overwhelmingly re-elected all 11 directors and ratified Simon & Edward, LLP as auditors for 2025 at the June 3 annual meeting, with 35.27% turnout. They greenlit a related-party land purchase from director Shuling Jiang via stock and warrants, potentially diluting shares over 20% and risking Nasdaq change-of-control scrutiny. The equity plan expanded to 15% of outstanding shares, auto-increasing 5% yearly from 2026. Continuity holds, but dilution looms.
8-K
Q1 loss shrinks; Taiwan land eyed
ABVC BioPharma slashed operating expenses 76% to $693,005 in Q1 2025, trimming net loss 68% to $944,190 from Q1 2024's $2.93 million. The company recognized a $7.67 million land asset in Taiwan, eyeing an AI-powered agricultural facility for sustainable botanical sourcing. This vertical integration push bolsters drug pipeline consistency. No assurance the project materializes amid financing risks.
10-Q
Q1 FY2025 results
ABVC BioPharma posted no revenue in Q1 FY2025 ended March 31, 2025, down from $1.2K a year earlier, as licensing milestones lagged. Operating expenses fell 76% y/y to $693K, driven by lower stock-based comp and R&D, yielding an operating loss of $693K versus $2.8M last year. Net loss narrowed to $944K from $2.9M, with EPS at -$0.06 on 15.0M shares (derived), while interest expense rose 15% y/y to $224K on convertible notes. Cash dipped to $152K from $248K, but warrant exercises brought in $412K; free cash flow not disclosed in the 10-Q. Acquired control of $7.7M Taiwan land for health ventures via subsidiary issuance. Nasdaq compliance hangs by a thread.
ABP
Abpro Holdings, Inc
0.20-0.00
ABVX
Abivax SA
98.94+4.70
AVBP
ArriVent BioPharma, Inc.
18.68-0.98
BCAB
BioAtla, Inc.
0.70-0.04
BIVI
BioVie Inc.
1.80-0.06
INMB
INmune Bio Inc.
1.82+0.00
NUVB
Nuvation Bio Inc.
5.26-0.11
RVPH
Reviva Pharmaceuticals Holdings
0.59+0.01
TOVX
Theriva Biologics, Inc.
0.31-0.02
VINC
Vincerx Pharma, Inc.
0.03+0.00